Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Federated Hermes Inc.

Key Points

• Federated Hermes Inc. has reduced its stake in Enliven Therapeutics by 41.3%, owning approximately $1.36 million in shares after selling nearly 49,000 shares in the first quarter.
• Recent insider transactions have seen COO Anish Patel and CEO Samuel Kintz sell shares, decreasing their respective holdings by 2.20% and 1.31%.
• Analysts have shown positive sentiment towards Enliven Therapeutics, with multiple reports increasing price targets, indicating an average target of $41.20 and a general "buy" rating.

Federated Hermes Inc. cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 41.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 69,051 shares of the company's stock after selling 48,501 shares during the period. Federated Hermes Inc. owned about 0.14% of Enliven Therapeutics worth $1,359,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Ameriprise Financial Inc. acquired a new position in shares of Enliven Therapeutics in the fourth quarter valued at approximately $789,000. Millennium Management LLC grew its holdings in shares of Enliven Therapeutics by 108.6% in the fourth quarter. Millennium Management LLC now owns 50,804 shares of the company's stock valued at $1,143,000 after purchasing an additional 26,449 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Enliven Therapeutics by 67.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company's stock worth $984,000 after acquiring an additional 17,546 shares during the last quarter. Rhumbline Advisers lifted its stake in Enliven Therapeutics by 4.9% in the first quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock worth $1,033,000 after acquiring an additional 2,466 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in Enliven Therapeutics by 15.3% in the fourth quarter. Wellington Management Group LLP now owns 80,916 shares of the company's stock worth $1,821,000 after acquiring an additional 10,746 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Robert W. Baird boosted their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 16th. The Goldman Sachs Group started coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a "buy" rating and a $37.00 price objective for the company. Finally, Jones Trading cut their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $41.20.

Insider Transactions at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 12,500 shares of the stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $21.40, for a total transaction of $267,500.00. Following the transaction, the insider directly owned 965,188 shares in the company, valued at $20,655,023.20. This represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer owned 940,392 shares in the company, valued at approximately $21,177,627.84. The trade was a 1.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 99,084 shares of company stock worth $2,046,719 in the last three months. Company insiders own 25.90% of the company's stock.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded down $0.21 on Friday, reaching $17.69. The stock had a trading volume of 574,228 shares, compared to its average volume of 386,894. The company has a market cap of $868.05 million, a price-to-earnings ratio of -9.21 and a beta of 0.93. The firm's fifty day moving average is $20.84 and its two-hundred day moving average is $19.98. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.